Biotech RadarJobs updated

COMPANY

Praxis Precision Medicines

HQ: Boston, MA source · praxismedicines.com ↗

Clinical Phase 3

137 open jobs · last seen Oct 23, 2026 · 20 sources

Praxis Precision Medicines is a fully integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. From company website Source · Oct 12, 2026

Keywords: Essential Tremor Post-traumatic Stress Disorder Focal Seizure SCN2A Encephalopathy SCN2A-DEE Epilepsy Major Depressive Disorder Developmental and Epileptic Encephalopathy 1 Tonic-Clonic Epilepsy Primary Generalized Seizure Epileptic Encephalopathy Focal Epilepsy SCN8A Encephalopathy Focal Onset Seizure Primary Generalized Epilepsy Stress Disorder Trauma and Stressor Related Disorders Mental Disorder PRAX-114 ulixacaltamide PRAX-562 vormatrogine PRAX-628 PRAX-944

Profile checked Oct 10, 2026

Since the raise (Jan 7, 2026): 137 of 137 open jobs were first seen after it.

137Open jobs$1.1BRaised (2 yrs)17Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Account Specialist (Cleveland, OH)United States - RemoteOct 22, 2026Oct 23, 2026
Senior Medical Science Liaison, Central (Multiple Territories)United States - RemoteOct 22, 2026Oct 23, 2026
Senior Medical Science Liaison, West (Multiple Territories)United States - RemoteOct 22, 2026Oct 23, 2026
Senior Medical Science Liaison, Southeast (Multiple Territories)United States - RemoteOct 22, 2026Oct 23, 2026
Senior Medical Science Liaison, South (Multiple Territories)United States - RemoteOct 22, 2026Oct 23, 2026

See all 137 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (137 open jobs at last check). source ↗
  2. Trial start Phase 3: Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures source ↗
  3. Raise Follow-on offering: $575M (total, as published), announced Jan 7, 2026. Source: company release on GlobeNewswire. source ↗
  4. Trial start Phase 3: Clinical Trial of Vormatrigine in Adult Patients With Epilepsy source ↗
  5. Raise Follow-on offering: $525M (total, as published), announced Oct 17, 2025. Source: company release on GlobeNewswire. source ↗
  6. Trial start Phase 3: A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety source ↗
  7. Trial start Phase 3: A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine source ↗
  8. Trial start Phase 1: A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628 source ↗
  9. Trial start Phase 2: An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures source ↗
  10. Trial start Phase 2/Phase 3: Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) source ↗
  11. Trial start 3: Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET) source ↗
  12. Trial start Phase 2/Phase 3: A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) source ↗
  13. Trial start Phase 1/Phase 2: A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy source ↗
  14. Trial start —: A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy source ↗
  15. Trial start Phase 2: A Clinical Trial of PRAX-114 in Participants With Essential Tremor source ↗
  16. Trial start Phase 2: A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder source ↗
  17. Trial start Phase 2: A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor source ↗
  18. Trial start Phase 2: A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder source ↗
  19. Trial start Phase 2/Phase 3: A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder source ↗
  20. Trial start Phase 2: A Clinical Trial of PRAX-944 in Participants With Essential Tremor source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 137

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Account Specialist (Cleveland, OH)United States - RemoteOct 22, 2026Oct 23, 2026Not stated
Senior Medical Science Liaison, Central (Multiple Territories)United States - RemoteOct 22, 2026Oct 23, 2026Not stated
Senior Medical Science Liaison, West (Multiple Territories)United States - RemoteOct 22, 2026Oct 23, 2026Not stated
Senior Medical Science Liaison, Southeast (Multiple Territories)United States - RemoteOct 22, 2026Oct 23, 2026Not stated
Senior Medical Science Liaison, South (Multiple Territories)United States - RemoteOct 22, 2026Oct 23, 2026Not stated
Senior Medical Science Liaison, Northeast (Multiple Territories)United States - RemoteOct 22, 2026Oct 23, 2026Not stated
HCP Personal Marketing Lead - Movement DisordersUnited States - RemoteOct 20, 2026Oct 21, 2026Not stated
Account Specialist (Manchester, NH)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Maine, ME)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Springfield, MA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Southeastern, MA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Baton Rouge, LA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Madison, WI)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Olympia, WAUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (New Hampshire North, NH)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Wilkes Barre, PA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Tucson, AZUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Spokane, WA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Shreveport, LA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (San Jose, CA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Roseville, CA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Palos Heights, ILUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Palm Springs, CA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (New London, CT)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Virginia Beach, VA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Metrowest, MAUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Northshore, MAUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Lafayette, INUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Johnson City, TN)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Jackson, MS)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Iowa City, IA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Gainesville, FLUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Fargo, NDUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Evansville, IN)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Eugene, ORUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Des Moines, IAUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist, Chattanooga, TNUnited States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Billings, MT)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Altoona, PA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Newark, DE)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Myrtle Beach, SC)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Asheville, NC)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Champlain Valley, VT)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Columbia, MD)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Palo Alto / San Francisco, CA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Texarkana, AR)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (East Cleveland, OH)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Danville, PA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialist (Burlington, MA)United States - RemoteOct 17, 2026Oct 18, 2026Not stated
Account Specialists (Peoria, IL)United States - RemoteOct 17, 2026Oct 18, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 137 jobs →

Funding

Raised: $1.1B. Last 2 years.

Clinical trials (lead sponsor) 17

RecordTitlePhaseStatusStartPrimary completion
NCT06087276Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)3RecruitingNov 2, 2023Oct 10, 2025 (actual)
NCT06999902Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)Phase 2/Phase 3CompletedDec 11, 2024May 14, 2026 (actual)
NCT07010471A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutriginePhase 3Active, not recruitingJul 9, 20252026-12 (estimated)
NCT07287163Clinical Trial of Vormatrigine in Adult Patients With EpilepsyPhase 3Enrolling by invitationOct 27, 2025May 31, 2028 (estimated)
NCT07019922A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyPhase 3RecruitingAug 13, 20252026-12 (estimated)
NCT07505004Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresPhase 3Active, not recruitingJan 29, 20262027-01 (estimated)
NCT05737784A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic EncephalopathyPhase 1/Phase 2Active, not recruitingApr 13, 2023Apr 1, 2026 (actual)
NCT06840925A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628Phase 1CompletedApr 28, 2025Jun 5, 2025 (actual)
NCT05818553A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)Phase 2/Phase 3Active, not recruitingAug 2, 2023Nov 12, 2025 (actual)
NCT06908356An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic SeizuresPhase 2RecruitingJan 10, 20252025-07 (estimated)
NCT05021991A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential TremorPhase 2CompletedOct 14, 2021Feb 9, 2023 (actual)
NCT05021978A Clinical Trial of PRAX-944 in Participants With Essential TremorPhase 2CompletedMar 3, 2020Mar 24, 2022 (actual)
NCT05407727A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic EncephalopathyNot listedCompletedApr 15, 2022Mar 31, 2023 (actual)
NCT05260541A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress DisorderPhase 2TerminatedJan 25, 2022Aug 1, 2022 (actual)
NCT05387642A Clinical Trial of PRAX-114 in Participants With Essential TremorPhase 2WithdrawnApr 5, 2022Jun 30, 2022 (actual)
NCT04969510A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive DisorderPhase 2CompletedJun 24, 2021Jul 15, 2022 (actual)
NCT04832425A Clinical Trial of PRAX-114 in Participants With Major Depressive DisorderPhase 2/Phase 3CompletedMar 30, 2021May 5, 2022 (actual)

Connect

See your connections at Praxis Precision Medicines on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback